KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Short-duration preoperative endocrine therapy alters molecular profiles to predict favourable outcome in ER+/HER2+ early breast cancer: a POETIC translational study.

Milana Bergamino Sirvén, Elena López-Knowles, Xixuan Zhu, Holly Tovey, Lucy Kilburn, Chris Holcombe, Anthony Skene, John Robertson, Judith M Bliss, Anastasia Alataki, Ian Smith, Eugene F Schuster, Mitch Dowsett, Maggie Chon U Cheang

EBioMedicine 118 105823

PMID40683772
PMCIDPMC12368290
DOI10.1016/j.ebiom.2025.105823
发表日期2025-07-19
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

BACKGROUND: About 15-20% of breast cancers (BC) overexpress Human Epidermal Growth Factor Receptor 2 (HER2+), and 50% of them are also oestrogen receptor positive (ER+). Patients with ER+/HER2+ BC with a limited response to systemic therapies are at an increased risk of relapse, thus understanding the mechanisms of resistance is crucial. This study investigates the changes in gene signature expression (ΔGSE) within ER+/HER2+ tumours and their intrinsic subtype (IS) in response to peri-operative aromatase inhibitors (POAI). METHODS: We analysed paired pre-treatment (baseline) and on-treatment (2wk) samples from 313 ER+/HER2+ BC from the POETIC trial using the BC360™ codeset. Early biological response to aromatase inhibitors (AI) was assessed by immunohistochemical Ki67 levels. Association of ΔGSE with biological response was evaluated using T-test and time to recurrence (TTR) with multivariable Cox regression models adjusted for clinicopathological variables. FINDINGS: The immunity-related signatures were significantly upregulated, while proliferation, TP53 surrogate mutational status and ER-signalling were downregulated (FDR <0·05) among POAI tumours with low Ki672wk. In the POAI, 79% (59/75) of Luminal B (LumB) at baseline shifted to Luminal A (LumA) at 2wk and LumA2wk was associated with better TTR compared to LumB2wk (HR 0·2; CI 95% 0·06-0·72, p = 0·01). Based on Akaike Information Criterion scores, Ki67 and IS at 2wk provided better fit of the multivariable Cox models over the variables at baseline when predicting TTR. INTERPRETATION: Assessing on-treatment IS after POAI for ER+HER2+ BC can help to identify a group of low-risk patients with LumA2wk with good outcomes on de-escalated treatment and patients that require additional treatments. FUNDING: Cancer Research UK (CRUK/07/015).

KM 提取结果

2 个 Figure · 6 个 KM 面板

进入结果中心
KM Figure2 个面板

Fig. 1

Fig. 1 Ki67 changes . Line plots of the baseline and surgery/on-treatment Ki67 levels coloured by Ki67 changes categories: High–High (H–H), High-Low (H–L), Low-High (L–H) and Low–Low (L–L) in a. POAI (n = 210) and b. control samples (n = 50). Kaplan Meier curves for TTR in POAI according to c. Ki67 2 wk High vs Low and d. Ki67 categories H–H, H-L and L–L. Cox regression analyses were all adjusted by clinicopathological variables.

C

TTR

Fig. 1 · Panel C

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel C 是同一 Fig. 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
D

TTR

Fig. 1 · Panel D

complete 待 EXE 对齐 预期 3 条 已提取 3 条

Panel D 是同一 Fig. 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 3:extreme jump曲线 3:extreme upward reversal
查看结果
KM Figure4 个面板

Fig. 4

Fig. 4 Intrinsic subtype and time to recurrence in POAI. Kaplan Meier curves for TTR according to intrinsic subtypes (4 classes) at a. baseline (n = 213), b. on-treatment timepoints (LumA as reference) (n = 213). c. Kaplan Meier curves for TTR according to LumA–LumA vs LumB-LumA (Univariable and multivariable cox regression analysis adjusted by clinicopathological variables, LumA–LumA as reference) (n = 113). d. Kaplan Meier curves for TTR according to LumB:LumA vs LumB:LumB and HER2-E:LumA vs HER2-E:HER2-E (LumB:LumA and HER2-E:LumA as reference) (n = 162). Cox regression analyses were all adjusted by clinicopathological variables.

A

TTR

Fig. 4 · Panel A

quality_warning 待 EXE 对齐 预期 4 条 已提取 3 条

Panel A 是同一 Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 4 条,实际恢复 3 条疑似图例或人工水平线:轨迹出现不合理的共同平台曲线 2:off origin start
查看结果
B

TTR

Fig. 4 · Panel B

quality_warning 待 EXE 对齐 预期 4 条 已提取 3 条

Panel B 是同一 Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 4 条,实际恢复 3 条疑似图例或人工水平线:轨迹出现不合理的共同平台曲线 1:off origin start
查看结果
C

TTR

Fig. 4 · Panel C

quality_warning 待 EXE 对齐 预期 3 条 已提取 2 条

Panel C 是同一 Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线缺失:预期 3 条,实际恢复 2 条曲线 1:short span曲线 3:short span曲线 3:very low support
查看结果
D

TTR

Fig. 4 · Panel D

quality_warning 待 EXE 对齐 预期 4 条 已提取 3 条

Panel D 是同一 Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 4 条,实际恢复 3 条疑似图例或人工水平线:轨迹出现不合理的共同平台曲线 2:off origin start
查看结果
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 2Fig. 2 Gene signature expression changes. Heatmap of log2 fold change in BC360 biological signature expression with samples sorted by changes in Ki67 categories and baseline Ki67%, for samples in a. POAI (n = 213) and b. control (n = 100) groups. T-tests were performed in control and POAI groups separately for all signatures to compare the expression levels between baseline and surgery/on-treatment. p-values were adjusted by False Discovery Rate (FDR). For heatmap visualisation, Genomic Risk was log2 transformed. Gene signatures were ordered by T-statistic in the POAI group. Higher T-statistic means the signature was upregulated at surgery/on-treatment and lower T-statistic means the signature was upregulated at baseline. c. Hierarchical clustering of BC360 biological signature expression changes from baseline to on-treatment (Log2FC) in POAI (n = 207) supervised by H–H, H-L, L–L Ki67 change categories.
非 KM Figure
Fig. 3Fig. 3 Intrinsic subtype changes. Shift of intrinsic subtype from baseline to surgery/on-treatment timepoints in a. POAI (n = 213) and b. control (n = 100) groups. Table showing intrinsic subtype shifts from baseline to on-treatment samples in c. POAI (n = 213) and d. control (n = 100) groups. Supervised hierarchical clustering of changes in gene signature expression shown as mean/standard deviation in POAI (n = 143) (e) and control (n = 88) (f) groups between the 5 Intrinsic subtype change groups. The F-statistic is the ratio of between-group variance and within-group variance. Abbreviations: LumA, Luminal A; LumB, Luminal B; HER2-E, HER2 enriched.
非 KM Figure